Home > News > European Patent Granted
September 2nd, 2004
European Patent Granted
Abstract:
Global nanotechnology company pSivida Limited, is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a further European patent for BioSilicon™. European Patent Number 1220659 relates to the invention of orally administrable pharmaceutical products (eg tablets, capsules, pellets and powders) that comprise porous and/or polycrystalline silicon (BioSilicon™). Oral administration of drugs remains the most favoured route of treatment, being painless and enabling the patient to self-administer. BioSilicon™, allows drug molecules to be held in nanosized pockets that release tiny pulses of drug as the BioSilicon™ dissolves.
Source:
pSivida
Bookmark:
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||